Abstract
Undoubtedly, the pharmacological treatment of schizophrenia has changed dramatically over the last 10 years. Large, double-blind, placebo-controlled trials have ushered the availability of each new antipsychotic. However, there has been an information lag because of the relative paucity of long term, comparative studies among second-generation antipsychotics. While we await such evidence, naturalistic studies have helped to provide useful information on the pattern of use, patient response, and tolerability of these new agents in clinical practice. This review provides an account of representative studies for each second generation antipsychotic, which illustrate the contributions of naturalistic studies to our understanding of the evolving pharmacotherapy of schizophrenia.
Keywords: Naturalistic, antipsychotics, schizophrenia, placebo-controlled
Current Medicinal Chemistry
Title: Naturalistic Studies of Second Generation Antipsychotics in the Treatment of Schizophrenia
Volume: 11 Issue: 3
Author(s): C. Simon Sebastian, William Glazer and Peter F. Buckley
Affiliation:
Keywords: Naturalistic, antipsychotics, schizophrenia, placebo-controlled
Abstract: Undoubtedly, the pharmacological treatment of schizophrenia has changed dramatically over the last 10 years. Large, double-blind, placebo-controlled trials have ushered the availability of each new antipsychotic. However, there has been an information lag because of the relative paucity of long term, comparative studies among second-generation antipsychotics. While we await such evidence, naturalistic studies have helped to provide useful information on the pattern of use, patient response, and tolerability of these new agents in clinical practice. This review provides an account of representative studies for each second generation antipsychotic, which illustrate the contributions of naturalistic studies to our understanding of the evolving pharmacotherapy of schizophrenia.
Export Options
About this article
Cite this article as:
Sebastian Simon C., Glazer William and Buckley F. Peter, Naturalistic Studies of Second Generation Antipsychotics in the Treatment of Schizophrenia, Current Medicinal Chemistry 2004; 11 (3) . https://dx.doi.org/10.2174/0929867043456025
DOI https://dx.doi.org/10.2174/0929867043456025 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Progressive Supranuclear Palsy: A Review
Current Alzheimer Research Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists
Current Topics in Medicinal Chemistry The Rabbit Syndrome: State of the Art
Current Clinical Pharmacology Noradrenaline in Parkinsons Disease: From Disease Progression to Current Therapeutics
Current Medicinal Chemistry Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry
Current Neuropharmacology Oxidative stress and Parkinson’s disease: New hopes in treatment with herbal antioxidants
Current Pharmaceutical Design Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Modulation of Monoaminergic Transporters by Choline-Containing Phospholipids in Rat Brain
CNS & Neurological Disorders - Drug Targets Positive Allosteric Modulators (PAMs) of Metabotropic Glutamate Receptor 5 (mGluR5) Attenuate Microglial Activation
CNS & Neurological Disorders - Drug Targets Src Family Kinases in the Central Nervous System: Their Emerging Role in Pathophysiology of Migraine and Neuropathic Pain
Current Neuropharmacology Phosphodiesterases as Therapeutic Targets for Huntington’s Disease
Current Pharmaceutical Design Drug Therapy for Patients with Eating Disorders
Current Drug Targets - CNS & Neurological Disorders A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation
Current Neuropharmacology Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review
Current Pharmaceutical Design Targeted D4 Dopamine Receptors: Implications for Drug Discovery and Therapeutic Development
Current Drug Targets Atypicality of Atypical Antipsychotics Revisited
Current Psychiatry Reviews Curcumin: Not So Spicy After All
Mini-Reviews in Medicinal Chemistry Minocycline Inhibits mTOR Signaling Activation and Alleviates Behavioral Deficits in the Wistar Rats with Acute Ischemia stroke
CNS & Neurological Disorders - Drug Targets Susceptibility Genes for the Side Effect of Antipsychotics on Body Weight and Obesity
Current Drug Targets